Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

140 Applying Pharmacogenomics in Therapeutics
Tai, Y.C., Domchek, S., Parmigiani, G., and Chen, S. (2007). Breast cancer risk among male
BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 99,
1811–1814.
Takeuchi, K., Choi, Y.L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., et al. (2009).
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based
diagnostic system for ALK-positive lung cancer. Clinical Cancer Research 15, 3143–3149.
Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., et al.
(2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England Journal of Medicine 354, 2531–2541.
Thompson, D., Easton, D.F., and Breast Cancer Linkage Consortium. (2002). Cancer incidence
in BRCA1 mutation carriers. Journal of the National Cancer Institute 94, 1358–1365.
Tulinius, H., Olafsdottir, G.H., Sigvaldason, H., Arason, A., Barkardottir, R.B., Egilsson, V.,
Ogmundsdottir, H.M., Tryggvadottir, L., Gudlaugsdottir, S., and Eyfjord, J.E. (2002).
The effect of a single BRCA2 mutation on cancer in Iceland. Journal of Medical
Genetics 39, 457–462.
van der Groep, P., van der Wall, E., and van Diest, P.J. (2011). Pathology of hereditary breast
cancer. Cellular Oncology 34, 71–88.
Walker, A.H., Jaffe, J.M., Gunasegaram, S., Cummings, S.A., Huang, C.S., Chern, H.D.,
Olopade, O.I., Weber, B.L., and Rebbeck, T.R. (1998). Characterization of an allelic variant
in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for
prostate cancer risk. Mutations in brief no. 191. Online. Human Mutation 12, 289.
Walsh, T., and King, M.C. (2007). Ten genes for inherited breast cancer. Cancer Cell 11,
103–105.
Walsh, T., Lee, M.K., Casadei, S., Thornton, A.M., Stray, S.M., Pennil, C., Nord, A.S.,
Mandell, J.B., Swisher, E.M., and King, M.C. (2010). Detection of inherited mutations
for breast and ovarian cancer using genomic capture and massively parallel
sequencing. Proceedings of the National Academy of Sciences of the United States of
America 107, 12629–12633.
Wang, J., Mougey, E.B., David, C.J., Humma, L.M., Johnson, J.A., Lima, J.J., and
Sylvester, J.E. (2001). Determination of human beta(2)-adrenoceptor haplotypes by
denaturation selective amplification and subtractive genotyping. American Journal of
Pharmacogenomics 1, 315–322.
Weinshilboum, R.M., and Sladek, S.L. (1980). Mercaptopurine pharmacogenetics: Monogenic
inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of
Human Genetics 32, 651–662.
Wilke, R.A., Ramsey, L.B., Johnson, S.G., Maxwell, W.D., McLeod, H.L., Voora, D.,
Krauss, R.M., et al. (2012). The clinical pharmacogenomics implementation consortium:
CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical
Pharmacology and Therapeutics 92, 112–117.
Win, A.K., Young, J.P., Lindor, N.M., Tucker, K.M., Ahnen, D.J., Young, G.P., Buchanan, D.D.,
et al. (2012). Colorectal and other cancer risks for carriers and noncarriers from families
with a DNA mismatch repair gene mutation: A prospective cohort study. Journal of
Clinical Oncology 30, 958–964.
Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H.,
Allred, D.C., et al. (2013). Recommendations for human epidermal growth factor
receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline update. Journal of Clinical Oncology
31, 3997–4013.
Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J.,
Dowsett, M., et al. (2007). American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth factor receptor
2 testing in breast cancer. Archives of Pathology & Laboratory Medicine 131, 18–43.